Skip to main content

Table 1 Patient characteristics based on the presence of CADM or anti-MDA-5 antibodies

From: Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan

    CADM α-MDA-5-positive
Years of sera collection Total number of DM patients (M:F) Mean age at onset (range) Number (%) of patients (M:F) Pvalue* Mean age at onset (range) Number (%) of patients (M:F) Pvalue** Mean age at onset (range)
T1 (1994 to 1995) 32 (12:20) 47.5 (4 to 80) 6 (18.8%) (2:4) P for difference = 0.012 45.5 (4 to 73) 2 (6.3%) (1:1%) P for difference = 0.003 53 (43 to 63)
T2 (1996 to 2003) 30 (6:24) 50.1 (15 to 79) 12 (40.0%) (1:11) P for trend = 0.003 50.7 (20 to 73) 10 (33.3%) (0:10) P for trend = 0.001 48.9 (20 to 66)
T3 (2004 to 2011) 33 (10:23) 43.6 (1 to 73) 18 (54.5%) (5:13)   40.8 (1 to 69) 14 (42.4%) (4:10)   44.4 (11 to 58)
  1. CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM in total DM. **Prevalence of anti-MDA-5 in total DM.